Here, gain‐ and loss‐of‐function studies are used to identify the therapeutic role of Pip4k2c in preventing CH and CF via inhibition of mTOR and TGFβ1 pathways, respectively. The gene discussed is TGFB1; the disease is cystic fibrosis.